PharmaCyte BiotechPMCB -0.30%32 PB Ratio is 0.21 as of Jun. 26, 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, PharmaCyte Biotech ranks better than 98.46% on this metric.
The historical rank and industry rank for PharmaCyte Biotech's PB Ratio or its related term are showing as below:
PMCB'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.21
Current: 0.21
During the past 13 years, PharmaCyte Biotech's highest PB Ratio was 0.21. The lowest was 0.00. And the median was 0.00.
PMCB's PB Ratio is ranked better than 98.46% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs PMCB: 0.21
During the past 12 months, PharmaCyte Biotech's average Book Value Per Share Growth Rate was -38.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 20.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PharmaCyte Biotech was 28.40% per year. The lowest was -252.40% per year. And the median was -15.35% per year.
Back to Basics: PB Ratio
PharmaCyte Biotech (NAS:PMCB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
PharmaCyte Biotech PB Ratio Related Terms
PharmaCyte Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PharmaCyte Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
PharmaCyte Biotech (PMCB) has a PB Ratio of 0.21 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #19 out of 1233 companies in the Biotechnology industry, placing it in the top 1.5%.
Is PharmaCyte Biotech's PB Ratio too high?
PharmaCyte Biotech's current PB Ratio is 0.21. The Biotechnology industry median PB Ratio is 2.80. PharmaCyte Biotech's value of 0.21 is 92.5% below this industry median. Based on the distribution chart, PharmaCyte Biotech ranks #19 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's PB Ratio compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #19 out of 1233 companies for PB Ratio. This places PharmaCyte Biotech in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. PharmaCyte Biotech's value of 0.21 is 92.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCyte Biotech's current PB Ratio of 0.21 is 92.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PharmaCyte Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current PB Ratio is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current PB Ratio of 0.21. The current PB Ratio is 0.21 and 92.5% below the Biotechnology industry median of 2.80. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current PB Ratio is 0.21 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
